Resuming Wegovy After a One-Month Interruption
After missing Wegovy 2.4 mg for over a month, you should restart the titration schedule from the beginning at 0.25 mg weekly rather than resuming at 2.4 mg. This approach is essential because the drug has been completely eliminated from the patient's system, and gastrointestinal tolerance must be re-established to prevent severe adverse events.
Why Restart Titration Is Necessary
When ≥3 consecutive weekly doses are missed, the standard titration schedule must be restarted rather than simply resuming the previous dose, because complete drug clearance eliminates the gastrointestinal adaptation that was built during the initial titration. 1
Semaglutide has a half-life of approximately 7 days, meaning that after one month (roughly 4 half-lives), the drug is essentially undetectable in the patient's system and all physiologic effects—including GI tolerance—have dissipated. 2
Skipping titration and restarting directly at 2.4 mg markedly increases the risk of severe nausea, vomiting, and diarrhea, potentially leading to treatment discontinuation and dehydration. 3
Recommended Restart Protocol
Follow this stepwise titration schedule:
| Week Range | Weekly Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | Re-establish baseline GI tolerance at the lowest approved dose [1] |
| Weeks 5–8 | 0.5 mg | Gradual escalation after confirming tolerability [1] |
| Weeks 9–12 | 1.0 mg | Continue building toward therapeutic dose [1] |
| Weeks 13–16 | 1.7 mg | Penultimate step for weight management indication [1] |
| Week 17+ | 2.4 mg | Target maintenance dose for obesity treatment [1] |
- The entire titration process will take approximately 16–20 weeks to reach the 2.4 mg maintenance dose, which is necessary to minimize gastrointestinal adverse events that occur in the majority of patients (nausea 44%, diarrhea 32%, vomiting 25%). 3
Critical Monitoring During Restart
During the first 4 weeks after restarting:
Assess gastrointestinal symptoms weekly (nausea, vomiting, diarrhea, abdominal pain) to detect intolerance early and adjust the titration pace if needed. 3
Monitor for signs of pancreatitis (persistent severe abdominal pain radiating to the back); discontinue semaglutide immediately if suspected, as pancreatitis has been reported with GLP-1 receptor agonists. 3
Check blood pressure every 4 weeks during dose escalation, because weight loss may necessitate reduction of antihypertensive medications. 3
Why You Cannot Skip Titration
Even though the patient previously tolerated 2.4 mg, restarting at that dose without titration creates a high risk of severe gastrointestinal adverse events because the physiologic adaptation to delayed gastric emptying has been lost during the one-month interruption. 3
Gradual dose escalation is essential to develop gastrointestinal tolerance; the 4-week interval between dose changes allows the body to adapt to progressively higher drug concentrations. 1, 3
Gastrointestinal adverse events are dose-dependent and transient, typically resolving within 4–8 weeks at each dose level when proper titration is followed. 4, 5
Expected Outcomes After Restart
Weight-loss efficacy should be evaluated at 12–16 weeks on the maximum tolerated dose; discontinue therapy if the patient achieves <5% body weight loss after 3 months, as early non-responders are unlikely to benefit from continued treatment. 3
Mean weight loss with semaglutide 2.4 mg is approximately 14.9% at 68 weeks when combined with lifestyle modifications (500-kcal daily deficit and ≥150 minutes/week of moderate-intensity physical activity). 4, 6
Approximately 86% of patients achieve ≥5% weight loss, 69% achieve ≥10% weight loss, and 50% achieve ≥15% weight loss when the full titration schedule is completed and maintained. 4
Contraindications to Verify Before Restart
Confirm the patient has no personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), as these are absolute contraindications to semaglutide therapy. 3
Screen for history of pancreatitis; use semaglutide with caution in these patients, though causality between GLP-1 receptor agonists and pancreatitis has not been definitively established. 3
Common Pitfall to Avoid
Do not resume at 2.4 mg simply because the patient previously tolerated that dose. The one-month interruption has eliminated all drug from the system and reset gastrointestinal tolerance to baseline, making the patient physiologically equivalent to a treatment-naïve individual who requires the full titration schedule to safely reach the maintenance dose. 3